← BIOCRYST PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($55.1m) ($65.8m) ($101.3m) ($108.9m) ($182.8m) ($184.1m) ($247.1m) ($226.5m) ($88.9m) $263.9m
Depreciation, Depletion and Amortization $483k $704k $770k $724k $748k $777k $1.4m $1.7m $1.2m $1.4m
Amortization of Debt Issuance Costs $558k $876k $885k $1.3m $2.4m — — — — $1.4m
Deferred Income Tax Expense (Benefit) — — — — — — — ($682k) ($354k) ($1.2m)
Share-based Payment Arrangement, Noncash Expense $8.5m $12.6m $9.4m $17.7m $14.8m $34.6m $44.7m $55.6m $65.4m $85.1m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — $2.2m $7.5m $8.8m
Share-based Payment Arrangement, Expense $8.5m $12.6m $9.4m $17.7m $14.8m $34.6m $44.7m $55.6m $65.4m $85.1m
Share-based Payment Arrangement, Expensed and Capitalized, Amount — — — — — — — — — $85.1m
Gain (Loss) on Disposition of Assets ($17k) $12k ($7k) — — — — — — —
Gain (Loss) on Disposition of Business — — — — — — — — — $3.6m
Gain (Loss) on Disposition of Other Assets — — — — — — — — — $550k
Gain (Loss) on Extinguishment of Debt — — — — ($2.0m) $55.8m $0 ($29.0m) $0 ($17.3m)
Income Tax Expense (Benefit) — $0 $0 $0 $0 $2.3m $2.7m $310k $1.9m $3.5m
Interest Expense Nonoperating — — — — — — — — $98.5m $78.9m
Operating Lease, Expense — — — $1.5m $1.8m $1.8m $2.5m $2.0m $2.3m $2.0m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Inventories ($1.1m) ($500k) $1.6m ($1.6m) $7.0m $8.8m $12.4m $1.4m $4.2m $1.6m
Increase (Decrease) in Accounts Payable ($10.5m) $3.8m $4.5m $11.7m $17.4m $39.4m ($22.4m) ($16.8m) ($62.4m) $57.8m
Proceeds from Stock Options Exercised $317k $1.6m $2.9m $1.2m $2.4m $15.8m $15.0m — — —
Inventory Write-down — — — — — — $932k $422k $1.4m $985k
Nonoperating Income (Expense) — — — — — — — — ($84.4m) ($73.6m)
Payments of Financing Costs — — — — — — $34k — — —
Restructuring Costs — — — — — — — — — $6.3m
Revenue from Contract with Customer, Including Assessed Tax — — $20.7m $48.8m $17.8m $157.2m $270.8m $331.4m $450.7m $874.8m
Net Cash Provided by (Used in) Operating Activities ($53.4m) ($41.1m) ($92.6m) ($89.6m) ($137.2m) ($142.2m) ($161.8m) ($95.1m) ($52.0m) $347.4m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $5.3m $328k $366k $343k $514k $2.4m $1.4m $2.2m $1.1m $2.5m
Net Cash Provided by (Used in) Investing Activities $23.3m ($66.4m) $4.8m $77.9m ($6.9m) $15.8m ($128.2m) ($131.5m) $52.6m ($13.7m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt — — — — — — — $300.0m $0 $0
Repayments of Long-term Debt — — — — — — — — — $300.0m
Proceeds from Issuance of Common Stock $317k $134.0m $53.4m $58.5m $93.3m $50.0m $0 $0 $3.4m $9.1m
Net Cash Provided by (Used in) Financing Activities $23.3m $135.7m $62.5m $99.1m $302.7m $359.7m $88.0m $32.5m ($5.8m) ($349.9m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $0 $71k $566k $362k ($936k) $1.3m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — ($25.3m) $87.4m $158.6m $233.4m ($201.5m) ($193.8m) ($6.1m) ($15.0m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $0 $71k $566k $362k ($936k) $91.3m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities — — — — — $900k $0 $22.1m $30.4m $23.7m
Income Taxes Paid, Net — — — — — $118k $3.5m $1.4m $1.6m $2.8m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.